TH-189: A Phase 2 Study of Nivolumab plus Ramucirumab in Patients with Recurrent Advanced Metastatic Non-Small Cell Lung Carcinoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Carcinoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. To participate in the study the following conditions must be met:
    2. Patients must have histologically or cytologically confirmed, refractory or recurrent, advanced non-small cell lung carcinoma
    3. Patients must have completed one line of prior therapy and must have received PD-1, PD-L1 and/or CTLA-4 immunotherapy
    4. Patients must have measurable disease, defined as at least one lesion that can be accurately measured

You may not be eligible for this study if the following are true:

    1. You will not be able to participate in the study if you have had:
    2. Prior ramucirumab treatment.
    3. Experienced any Grade 3-4 GI bleeding within 3 months prior to first dose of protocol therapy
    4. Been currently receiving any other experimental drugs or medications that affect the immune system

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.